Enlivex Therapeutics Ltd

NASDAQ:ENLV  
5.06
-0.01 (-0.20%)
Regulatory, Earnings Announcements

Enlivex Receives Notice Of Allowance For U.S. Patent Application Covering Methods Of Treating Sepsis With Allocetra™

Published: 08/03/2022 12:24 GMT
Enlivex Therapeutics Ltd (ENLV) - Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis With Allocetra™.
Enlivex Therapeutics Ltd- Expects That This New Patent Will Be Issued in United States in Q4 of 2022.
Enlivex Therapeutics Ltd- Sepsis Program Includes an Ongoing Placebo-controlled, Randomized, Dose-finding, Multi-center Phase Ii Trial.
Enlivex Therapeutics Ltd- Interim Results From Multi-center Phase Ii Trial Are Expected in Q1 of 2023.
Enlivex Therapeutics Ltd- Top-line Data From Multi-center Phase Ii Trial Are Expected in Q3 of 2023.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.45

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.37

More details on our Analysts Page.